Default company panoramic image
D3dce6fe 0f4d 4004 9e4c 27407c51cc8a

Catylix, Inc.

Exploiting the importance of fluorine-containing functionality to develop novel reagents and building blocks to, leading to new bioactive chemical entities.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Burbank, CA, USA
  • Currency USD
  • Founded 2011
  • Employees 0
  • Website catylix.com

Company Summary

Catylix was created to exploit the importance of fluorine-containing functionality for improving the pharmacokinetic properties of bioactive compounds. Using proprietary chemistry for introducing fluoroalkyl groups into compounds, Catylix plans to use its novel chemistries to enable production of fluorine-containing NCEs and discover and patent novel compositions of matter. Applications are anticipated as new drugs and crop protection agents.

Team

  • Default avatar
    David Rozzell
    CEO and Co-Founder
    Unconfirmed

    Dr. David Rozzell earned a Ph.D. In chemistry from Harvard University and has spent 25 years working in the biotechnology industry with a specialization in the area of biocatalysis and chiral synthesis. Most recently, Dr. Rozzell was the founder and CEO of BioCatalytics, Inc, a company specializing in the development of novel enzymes for the pharmaceutical industry. . BioCatalytics, Inc. was acquired by Codexis, Inc. in July 2007.

  • Default avatar
    John F. Hartwig
    Co-Founder
    Unconfirmed

    Professor John F. Hartwig is the Henry Rapoport Professor of Chemistry at the Univertsity of clifornia at Berkeley, moving from his previous position at the University of Illinois in mid-2011. Professor Hartwig's research focuses on the discovery and understanding of new reactions catalyzed by transition metal complexes. In addition to technology on fluoralkylation licensed to Catylix, he has developed numerous other chemistries used world-wide.

  • Default avatar
    Brian M. Adger
    Co-Founder
    Unconfirmed

    Dr. Brian Adger has more than 35 years experience in the pharmaceutical and chemical industries. He has held senior positions at SmithKline French (now GSK), Sterling Drug (now part of Sanofi), Great Lakes Chemical Corporation and was a founding director of Chiroscience Ltd. Since 1997 Dr. Adger has been an independent consultant and has consulted for more than 50 companies internationally. Currently he is Chairman of the SAB for Johnson Matthey.

Advisors

  • Default avatar
    Wilson Sonsini Goodrich & Rosati
    Lawyer
    Unconfirmed
    Default avatar
    To be hired
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Illinois Ventures
    Unconfirmed
    Default avatar
    David Hitz
    Unconfirmed